Navigation Links
Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of,Erbitux for Colorectal and Head and Neck Cancer Patients

ancer may occur in the epithelial cells of any tissue or organ in the head and neck region excluding the eyes, brain, ears, thyroid or esophagus. Most head and neck cancers occur in the oral cavity (43%) followed by the pharynx (33%) and the larynx (24%).(4) The estimated incidence of head and neck cancers in Europe is around 140,000 annually, with over 65,000 deaths per year.(5) Currently, median survival for patients with recurrent or metastatic disease is only about six months.(6)

(a) CRYSTAL: Cetuximab combined with iRinotecan in first line therapY for metaSTatic colorectAL cancer
(b) OPUS: OxaliPlatin and cetUximab in firSt-line treatment of mCRC
(c) EXTREME: ErbituX in first line Treatment of REcurrent or MEtastatic head & neck cancer
(d) EPIC: European Prospective Investigation of Cancer
(e) LABEL: Latin American ErBitux prE-License study
(f) MABEL: Monoclonal Antibody ErBitux in a European Pre-License Study
(g) EVEREST: Evaluation of Various ErBitux REgimens by means of Skin and Tumour biopsies

About ERBITUX
ERBITUX® is a first-in-class and highly active IgG1 monoclonal antibody targeting the epidermal growth factor receptor (EGFR). As a monoclonal antibody, the mode of action of Erbitux is distinct from standard non-selective chemotherapy treatments in that it specifically targets and binds to the EGFR. This binding inhibits the activation of the receptor and the subsequent signal-transduction pathway, which results in reducing both the invasion of normal tissues by tumor cells and the spread of tumors to new sites. It is also believed to inhibit the ability of tumor cells to repair the damage caused by chemotherapy and radiotherapy and to inhibit the formation of new blood vessels inside tumors, which appears to lead to an overall suppression of tumor growth.

The most commonly reported side effect with Erbitux is an acne-like skin rash that seems to be correlated with a good response to
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
2. Merck at ASCO 2007: Encouraging Results in Progression-Free Survival in Patients With Aggressive Brain Tumors (glioblastoma) Using Cilengitide in Phase I/IIa Study
3. Merck at ASCO 2007: New Data Demonstrate the Value of UFT as an Important Treatment Option for Patients With Metastatic Colorectal Cancer
4. New England Journal of Medicine Publishes New Data on Gardasil, Mercks Cervical Cancer Vaccine
5. Merck Serono Announces Presentation of Phase III Clinical Data on Safinamide in Parkinson’s Disease at the American Academy of Neurology 59th Annual Meeting
6. AEterna Zentaris Partner, Spectrum, Discloses Detailed Phase 2 Data for Ozarelix, in BPH at Annual AUA Meeting
7. Spectrum Pharmaceuticals Announces Data From Three Oncology Programs Presented at the American Association of Cancer Research Annual Meeting
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
10. Studies of Drug Resistance May Lead to Individual Therapy for Rare Cancers
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
(Date:8/21/2014)... Texas , Aug. 21, 2014  eRelevance ... services company, announced today that it has completed ... (EMR) solution for Plastic Surgery and Dermatology practices. ... even more value to healthcare practices using Nextech," ... of eRelevance Corporation. "Using information from the EMR ...
(Date:8/21/2014)... 2014 The spinal column is one of the ... carried to and from the brain through the column control ... Injury or ailment here can be life altering, and leave ... control over their body. Though back injury and disease can ... are more options available to make things better than ever ...
(Date:8/21/2014)... , Aug. 21, 2014  Publicis Groupe ... Hartley , Managing Partner and Healthcare Industry Group Leader, ... 100, which recognizes the most inspiring people in the ... leaders in research and development, marketing, technology, creativity, strategy ... in 2006 as a partner in its leading Rosetta ...
Breaking Medicine Technology:eRelevance Corporation Integrates with Nextech Electronic Medical Records 2Don't Live in Pain: Four Life Improving Benefits of Back Surgery 2Shannon Hartley Shines in PharmaVOICE 100 2
(Date:8/21/2014)... Sasha is a 10 year old Alaskan malamute, ... little older, and is having trouble getting up and down, ... have an owner who purchased a Butler Mobility Inclined Platform ... could no longer get up and down the stairs from ... She had tried a stair lift, but had to transfer ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 The Onder ... and product liability law, announces the launch of a ... comprehensive information on morcellator surgery lawsuits for ... FDA morcellator cancer warning and the July 2014 morcellator ... the April 17, 2014 FDA warning on morcellator surgery ...
(Date:8/21/2014)... 21, 2014 Pleio, Inc., a ... launching a new suite of services for retail ... retail pharmacy by applying proven behavior shaping programs ... in increased medication adherence, higher PDC scores and ... Pleio’s PDC-targeted offerings align retail’s desire to meet ...
(Date:8/21/2014)... NJ. August 21, 2014. Researchers have published a ... outcomes of patients with motor complete spinal cord ... in functioning at discharge and follow-up among patients ... of print on August 2 by the ... 10.1016/j.apmr.2014.07.398). Findings included small but significant differences in ...
(Date:8/21/2014)... announces the immediate release of Care of the ... CHEST Consensus Statement today in the Online First ... the global health-care community cares for patients with ... guide ethical decision-making, coordination of care, resource conservation, ... by over 100 clinicians and experts representing a ...
Breaking Medicine News(10 mins):Health News:Sasha Gets a Butler Mobility Inclined Platform Lift 2Health News:The Onder Law Firm Launches National Morcellator Cancer Lawsuit Center Website for Morcellator Surgery Lawsuits at MorcellatorCancerLawsuitCenter.com 2Health News:The Onder Law Firm Launches National Morcellator Cancer Lawsuit Center Website for Morcellator Surgery Lawsuits at MorcellatorCancerLawsuitCenter.com 3Health News:Pleio, Inc. Expands Adherence Offerings For Retail Pharmacy 2Health News:Researchers examine impact of race and ethnicity in motor complete spinal cord injury 2Health News:CHEST releases new expert guidance in care of the critically ill and injured 2
... often been associated with serious side-effects. Researchers at the ... mice, found a way of utilising the positive effects ... is acted on, current research at the Academy shows. ... PNAS (Proceedings of the National Academy of Sciences). ...
... bacterial DNA that often carries antibiotic resistance is a master ... widely differing bacterial species, shows a study made by ... with Chalmers University of Technology. The results are published in ... More and more bacteria are becoming resistant to our ...
... , MONDAY, April 11 (HealthDay News) -- Young mothers ... have children, and they also consume more saturated fat, ... Examining data from Project EAT (Eating and Activity ... of Minnesota focused on the link between parental status, ...
... Normal daily fluctuations in blood pressure aren,t linked with the ... heart attack or stroke in the morning, a new study ... who underwent three types of sleep/wake cycle experiments designed to ... daily rise and fall in blood pressure. In all ...
... pain can significantly reduce disability in older adults, according to ... newsletter from The Gerontological Society of America ... Annual Scientific Meeting in November 2010, the current WHAT,S HOT ... managing pain and preserving function, and methods to improve the ...
... , SUNDAY, April 10 (HealthDay News) -- Obese patients taking ... lost an average of 22 pounds over a year, while ... study has found. Qnexa is a combination of ... the United States, currently available under a variety of brand ...
Cached Medicine News:Health News:Antibiotic resistance spreads rapidly between bacteria 2Health News:Having Kids Might Make Young Women Heavier, Less Fit 2Health News:Having Kids Might Make Young Women Heavier, Less Fit 3Health News:Effective pain management crucial to older adults' well-being 2Health News:Experimental Weight-Loss Drug Seems to Work: Study 2Health News:Experimental Weight-Loss Drug Seems to Work: Study 3Health News:Experimental Weight-Loss Drug Seems to Work: Study 4
All BioWhittaker Cell Culture Reagent and Buffer products are manufactured in accordance with cGMP regulations and are cell culture tested to assure compatibility. , Typical Properties, Sterility : ...
...
... White to buff-colored powder Activity: >=590g of gentamicin/mg (dry ... tests Limit of Methanol: Specific Rotation (25C): +107 ... H 2 O): 3.5 to 5.5 Loss on drying: ... : 25-50% C 2 + C 2a : ...
... Gentamycin sulfate is effective against gram ... as mycoplasma, by interfering with bacterial protein ... of ribosomes. Its suggested working concentration of ... and mammalian cells, thereby making a gentler ...
Medicine Products: